STEM CELL part 27

Stem cell 2

 

There is obviously a moral obligation to provide new and better treatments for patients. But there are also obstacles on the road, regulatory as well as technical. If the problem of standardization, in particular of induced pluripotent stem cell lines, is not addressed, this will create regulatory hurdles as long as the FDA regards every cell line as a new treatment. Moreover, if cell therapies are to be commercially successful and affordable, solutions to the problem of scaling up have to be found.

(Goran Hermeren, Prof. em. Medical ethics, Lund University)

Advertisements

About azaleaazelia

A nice person... :)
This entry was posted in Tak Berkategori. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s